CANF Can-Fite BioPharma Ltd. Annual reports only
Pharmaceutical Preparations · NYSE · SEC CIK 1536196 · Fiscal year ends 12/31
Financial factors as of 2025-12-31 (FY2025), by fiscal year; growth vs the previous fiscal year
Growth
TTM revenue YoY-39.9%
TTM net income YoY-24.7%
TTM EPS YoY45.0%
Revenue 3-yr CAGR-20.6%
Net income 3-yr CAGR—
Margins
Gross margin—
Operating margin-2,456.8%
Net margin-2,426.7%
FCF margin-2,210.1%
EBITDA margin-2,450.9%
Returns
ROE-178.2%
ROA-105.5%
ROIC (approx.)-2,329.0%
Asset turnover0.04x
Leverage & solvency
Liabilities / assets41.2%
Debt / equity0.00x
Current ratio3.46x
Interest coverage-35.04x
Cash quality & payout
Operating cash flow / net income0.91x
Accruals ratio-9.4%
Payout ratio—
Capex / revenue0.5%
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | FY20252025-12-31 | FY20242024-12-31 | FY20232023-12-31 | FY20222022-12-31 | FY20212021-12-31 |
|---|---|---|---|---|---|
| Income statement | |||||
| Revenue | $405,000 | $674,000 | $743,000 | $810,000 | $853,000 |
| R&D expense | $6.69M | $5.76M | $5.98M | $7.76M | $9.85M |
| SG&A expense | $3.66M | $3.05M | $2.96M | $3.14M | $3.85M |
| Operating income | -$9.95M | -$8.13M | -$8.20M | -$10.10M | -$12.84M |
| Interest expense | $284,000 | $291,000 | $506,000 | -$222,000 | — |
| Pretax income | -$9.83M | -$7.88M | -$7.63M | -$10.17M | -$12.62M |
| Net income | -$9.83M | -$7.88M | -$7.63M | -$10.17M | -$12.62M |
| EBITDA | -$9.93M | -$8.12M | -$8.18M | -$10.08M | -$12.83M |
| EPS (basic) | -5.97 | -10.86 | -17.92 | -0.01 | -0.03 |
| EPS (diluted) | -5.97 | -10.86 | -17.92 | -0.01 | -0.03 |
| Weighted avg. shares (diluted) | 1.65M | 725,309 | 426,111 | 815.75M | 553.08M |
| Banking | |||||
| Net interest income | — | — | — | -$77,000 | $227,000 |
| Balance sheet | |||||
| Cash & equivalents | $5.53M | $4.83M | $4.28M | $2.98M | $4.39M |
| Short-term investments | $1,000 | $5,000 | $19,000 | $8,000 | $237,000 |
| Current assets | $9.44M | $8.98M | $9.91M | $9.16M | $20.07M |
| PP&E, net | $5,000 | $27,000 | $29,000 | $42,000 | $47,000 |
| Total assets | $9.51M | $9.12M | $9.99M | $9.28M | $20.25M |
| Current liabilities | $2.73M | $2.05M | $2.02M | $2.50M | $2.73M |
| Total liabilities | $3.92M | $3.68M | $3.75M | $4.81M | $5.87M |
| Shareholders' equity | $5.59M | $5.44M | $6.24M | $4.47M | $14.38M |
| Shares outstanding | 2.62M | 994,394 | 1.36B | 815.75M | 815.75M |
| Cash flow statement | |||||
| Operating cash flow | -$8.95M | -$7.64M | -$8.44M | -$10.80M | -$9.86M |
| Capital expenditure | $2,000 | $5,000 | $2,000 | $9,000 | $11,000 |
| Free cash flow | -$8.95M | -$7.64M | -$8.44M | -$10.81M | -$9.87M |
| Investing cash flow | -$2,000 | $1.50M | $498,000 | $9.50M | -$14.51M |
| Financing cash flow | $9.64M | $6.71M | $9.14M | — | $20.46M |
| Depreciation & amortization | $24,000 | $7,000 | $15,000 | $14,000 | $14,000 |
| Stock-based compensation | $340,000 | $362,000 | $261,000 | $263,000 | $466,000 |
| Dividends paid | — | — | — | — | $2.59M |
Free plan shows the latest 5 periods; Pro shows all 11 🔒
· This company files only annual reports with the SEC (20-F for foreign issuers), so there is no quarterly data; factors are by fiscal year and growth is vs the previous fiscal year.
· This company does not report gross profit in XBRL.
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-18 06:30.